Premium
Misconceptions About Calcimimetics
Author(s) -
NEMETH E.F.
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1346.044
Subject(s) - cinacalcet , calcimimetic , calcium sensing receptor , allosteric modulator , allosteric regulation , chemistry , drug discovery , parathyroid hormone , hyperparathyroidism , pharmacology , receptor , secondary hyperparathyroidism , calcium , medicine , endocrinology , biochemistry , organic chemistry
Calcimimetics are ligands that activate the calcium receptor. Some are small molecules and of these, the most extensively studied are phenylalkylamines like cinacalcet. This compound is a positive allosteric modulator that selectively targets the parathyroid calcium receptor to inhibit the secretion of parathyroid hormone. Cinacalcet is the first calcimimetic compound to attain regulatory approval for the treatment of hyperparathyroidism resulting from end‐stage renal disease. The discovery of calcimimetics and the receptor they act on are considered with the intent of extracting lessons relevant to medical research and the discovery of new drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom